Page last updated: 2024-11-12

echistatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

echistatin: 49 amino acid residues given in first source; from the venom of the viper Echis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16132434
MeSH IDM0161942

Synonyms (2)

Synonym
echistatin
129038-42-2

Research Excerpts

Overview

Echistatin is a member of the disintegrin family of peptides and a potent inhibitor of platelet aggregation and cell adhesion. It is a 49 amino acid protein isolated from the venom of a viper (Echis carinatus) and is one of the smallest natural adhesive ligands.

ExcerptReferenceRelevance
"Echistatin (Ech) is a short disintegrin with a long "( Structural Insight into Integrin Recognition and Anticancer Activity of Echistatin.
Chang, YT; Chen, CY; Chen, JF; Chen, YC; Cheng, CH; Chuang, WJ; Huang, CH; Shiu, JH, 2020
)
2.23
"Echistatin is an RGD cyclic peptide and an antagonist of αvβ3 integrin."( Disintegrin targeting of an αvβ3 integrin-over-expressing high-metastatic human osteosarcoma with echistatin inhibits cell proliferation, migration, invasion and adhesion in vitro.
Bouvet, M; Hoffman, RM; Kanaya, F; Kimura, H; Kiyuna, T; Sugimoto, N; Tome, Y; Tsuchiya, H, 2016
)
1.37
"Echistatin (Ech) is a potent inhibitor of integrins and was isolated from snake Echis carinatus. "( Expression in Pichia pastoris and characterization of echistatin, an RGD-containing short disintegrin.
Chang, YS; Chang, YT; Chen, YC; Cheng, CH; Chuang, WJ; Huang, CH; Lee, JC; Shiu, JH, 2012
)
2.07
"Echistatin is a potent antagonist of the integrins alpha(v)beta3, alpha5beta1 and alpha(IIb)beta3. "( Conformation and concerted dynamics of the integrin-binding site and the C-terminal region of echistatin revealed by homonuclear NMR.
Calvete, JJ; Celda, B; Esteve, V; Kovacs, H; Monleón, D, 2005
)
1.99
"Echistatin is a 49-amino-acid protein from Echis carinatus venom. "( Assignment of all four disulfide bridges in echistatin.
Bauer, M; Degenhardt, C; Kozikowski, B; Sun, Y, 1993
)
1.99
"Echistatin is a viper venom disintegrin containing RGD loop maintained by disulfide bridges. "( Significance of RGD loop and C-terminal domain of echistatin for recognition of alphaIIb beta3 and alpha(v) beta3 integrins and expression of ligand-induced binding site.
Marcinkiewicz, C; McLane, MA; Niewiarowski, S; Vijay-Kumar, S, 1997
)
1.99
"Echistatin is a 49-amino-acid peptide belonging to the family of disintegrins that are derived from snake venoms and are potent inhibitors of platelet aggregation and cell adhesion. "( Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor.
Armstrong, L; Catino, JJ; Kumar, CC; Malkowski, M; Maxwell, E; Nie, H; Rogers, CP, 1997
)
2
"Echistatin is a member of the disintegrin family of peptides and a potent inhibitor of platelet aggregation and cell adhesion. "( Chloramine T-induced structural and biochemical changes in echistatin.
Armstrong, L; Kumar, CC; Nie, H; Tsarbopoulos, A; Vijay-Kumar, S; Zhang, R, 1998
)
1.99
"Echistatin is a disintegrin that blocks alphavbeta3."( Identification and characterization of endothelial glycoprotein Ib using viper venom proteins modulating cell adhesion.
Darzynkiewicz, Z; Kowalska, MA; Lopez, JA; Niewiarowski, S; Romo, GM; Tan, L, 1999
)
1.02
"Echistatin is a 49 amino acid protein isolated from the venom of a viper (Echis carinatus) and is one of the smallest natural adhesive ligands that interacts with integrin-type receptors through an Arg-Gly-Asp (RGD) sequence. "( Three-dimensional structure of echistatin, the smallest active RGD protein.
Atkinson, RA; Pelton, JT; Saudek, V, 1991
)
2.01

Actions

Echistatin did not cause Mn2+ influx, and 10 microM nifedipine, 10 nM omega-conotoxin, 5 mM Ni2+, or Cd2+ did not prevent [Ca2+]i change.

ExcerptReferenceRelevance
"Echistatin could inhibit postoperative PCO occurrence and development in diabetic rabbit eyes, which may be related to down-regulation the expression of ILK and inhibition the PI3-K/Akt and ERK1/2 pathways."( Echistatin prevents posterior capsule opacification in diabetic rabbit model via integrin linked kinase signaling pathway.
Chen, Y; Liang, H; Lin, F; Tan, S, 2015
)
3.3
"Echistatin did not cause Mn2+ influx, and 10 microM nifedipine, 10 nM omega-conotoxin, 5 mM Ni2+, or Cd2+ did not prevent [Ca2+]i change."( Soluble alpha v beta 3-integrin ligands raise [Ca2+]i in rat osteoclasts and mouse-derived osteoclast-like cells.
Hoyer, JR; Hyman, JL; Rodan, GA; Tanaka, H; Wesolowski, G; Zimolo, Z, 1994
)
1.01

Treatment

Echistatin treatment down-regulated the phosphorylation of pp125FAK in fibronectin-adherent cells in a dose- and time-dependent fashion. The echistsatin-treated animals reperfused at 46 +/- 5 min with a reperfusion incidence of 100% (5/5)

ExcerptReferenceRelevance
"Echistatin treatment down-regulated the phosphorylation of pp125FAK in fibronectin-adherent cells in a dose- and time-dependent fashion."( Echistatin induces decrease of pp125FAK phosphorylation, disassembly of actin cytoskeleton and focal adhesions, and detachment of fibronectin-adherent melanoma cells.
Belisario, MA; Di Martino, E; Di Natale, P; Esposito, S; Garbi, C; Nitsch, L; Squillacioti, C; Staiano, N, 1997
)
2.46
"Echistatin treatment increased osteoclast-covered bone surface by about 50%."( Histomorphometric evidence for echistatin inhibition of bone resorption in mice with secondary hyperparathyroidism.
Duong, L; Leu, CT; Masarachia, P; Rodan, G; Yamamoto, M, 1998
)
1.31
"The echistatin-treated animals reperfused at 46 +/- 5 min with a reperfusion incidence of 100% (5/5)."( Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
Garsky, VM; Holahan, MA; Mellott, MJ; Shebuski, RJ, 1991
)
0.97
"Treatment with echistatin significantly attenuated load-induced degranulation without compromising cell viability."( Mechanical loading promotes mast cell degranulation via RGD-integrin dependent pathways.
Carver, W; Fowlkes, V; Goldsmith, EC; Wilson, CG, 2013
)
0.73

Pharmacokinetics

ExcerptReferenceRelevance
"Development of alphavbeta3-integrin inhibitors has been hampered by a lack of pharmacodynamic endpoints to identify doses that inhibit alphavbeta3 in vivo."( A functional radioreceptor assay of alpha-V-beta-3 (alphavbeta3) inhibitors in plasma: application as an ex vivo pharmacodynamic model.
Anaclerio, B; Baciu, P; Chaikin, MA; De Vries, GW; Edelman, J; Eisennagel, SH; Guo, Z; Leonard, K; Manthey, CL; Marugan, JJ; Molloy, CJ; Ni, M; Pan, W; Tomczuk, BE, 2005
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
" These results suggest that DOX in combination with a disintegrin has potential to treat osteosarcoma and that αvβ3 integrin may be a target for osteosarcoma."( The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing ανβ3 integrin in chick embryo and nude mouse models.
Bouvet, M; Hoffman, RM; Kanaya, F; Kimura, H; Sugimoto, N; Tome, Y; Tsuchiya, H, 2016
)
0.78

Dosage Studied

Echistatin binding was measured in the presence of plasma harvested from rats dosed with select compounds. A dose-response significant inhibition of the capillary-like formation was detected.

ExcerptRelevanceReference
" A dose-response significant inhibition of the capillary-like formation was detected when increasing concentrations of tamoxifen, ilomastat, or echistatin were added for 1 week to the culture medium of the ERCT."( In vitro evaluation of the angiostatic potential of drugs using an endothelialized tissue-engineered connective tissue.
Auger, FA; Berthod, F; Germain, L; Tremblay, PL, 2005
)
0.53
" Echistatin binding was measured in the presence of plasma harvested at timed intervals from rats dosed with select compounds."( A functional radioreceptor assay of alpha-V-beta-3 (alphavbeta3) inhibitors in plasma: application as an ex vivo pharmacodynamic model.
Anaclerio, B; Baciu, P; Chaikin, MA; De Vries, GW; Edelman, J; Eisennagel, SH; Guo, Z; Leonard, K; Manthey, CL; Marugan, JJ; Molloy, CJ; Ni, M; Pan, W; Tomczuk, BE, 2005
)
1.24
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (180)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (2.22)18.7374
1990's81 (45.00)18.2507
2000's70 (38.89)29.6817
2010's24 (13.33)24.3611
2020's1 (0.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.45 (24.57)
Research Supply Index5.22 (2.92)
Research Growth Index6.00 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (2.17%)6.00%
Case Studies1 (0.54%)4.05%
Observational0 (0.00%)0.25%
Other179 (97.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]